



### Systems-based Pharmaceutics

Progress update on turning the vision into reality

Sean Bermingham – VP Life Sciences, Consumer Goods and Specialty & Agrochemicals




















### Systems-based Pharmaceutics

A holistic approach to the development and optimisation of drug manufacture and drug delivery

#### Pharmaceutical systems



#### **CPPs & Disturbances**




### **CQAs & Process KPIs**



#### The "Pragmatic" Approach – and its pitfalls






- Essentially, a sequential approach
  - "silo thinking" reflected in organisational structures, tools, ...
- Too many iterations between ...
  - consecutive manufacturing steps
  - product design (formulation) and manufacturing process design
    - bioavailability targets and drug product/process development
  - R&D and manufacturing (Tech Transfer)
- ... and other inefficiencies
  - no central repository of consistent knowledge
  - many, long learning curves



#### Systems-based Pharmaceutics – I






 Use an integrated system model to quantify effects of CPPs & disturbances on CQAs, process economics, operability, safety

#### Systems-based Pharmaceutics – II





- Efficiently/effectively explore decision space
  - formal optimisation to eliminate trial-and-error
- Manage risk by quantifying impact of uncertainty
  - model uncertainties / gaps in process knowledge
     external disturbances, e.g. excipient quality

#### Systems-based Pharmaceutics – III



- A formal framework for the capture and generation of knowledge both current and future
  - support pharma eco-system
    - companies, universities, research organisations, suppliers
  - facilitate consistency, quality assurance
  - ...across different stages of product/process lifecycle: R&D, Manufacturing, ...
- ...and the effective deployment and exploitation of this knowledge in a sustainable and secure manner
  - make benefits of models available to all stakeholders
  - ensure traceability/auditability of model-based decisions
- Share what's common across the industry while supporting the development of competitive advantage where appropriate
  - common "language" for effective, industry-wide transfer of knowledge & ideas
  - facilitate regulatory approval





## An ambitious vision shared by major pharma companies


#### Formation of Systems-based Pharmaceutics Alliance



#### Systems-based Pharmaceutics Alliance

A single model-based framework for drug substance manufacturing, drug product manufacturing,

Systems-based Pharmaceutics Alliance formed



The SbP Alliance aims to develop a single model-based framework for drug substance manufacturing, drug product manufacturing, oral absorption and pharmacokinetics.

It will seek to establish best practices in the application of model-based techniques which will be incorporated in validated commercial quality computer software for the solution of industrially important problems.

To more rapidly meet the Alliance's objectives, we are further exploring opportunities to partner with additional, interested companies.





#### Independent of SbP Alliance discussions ...



# Linking Process Engineering to Product Performance A roll compaction case study

Gavin Reynolds Emmanuela Gavi

Pharmaceutical Development, Macclesfield, UK

AstraZeneca 🎺


1

Global Medicines Development | Pharmaceutical Developme

Advanced Process Modelling Forum, London, April 2013

## Independent of SbP Alliance discussions ... Tablet manufacturing (adapted from Reynolds & Gavi, 2013)









## Independent of SbP Alliance discussions ... Tablet manufacturing (adapted from Reynolds & Gavi, 2013)







Tablet Tensile Strength (MPa)

Compression Force (kN)



## Systems-based Pharmaceutics = QbD?

#### QbD and its uptake in the pharmaceutical industry



- QbD is a systematic approach to development that
  - begins with predefined objectives
  - emphasizes product and process understanding and process control
  - is based on sound science and quality risk management
- What we have heard from our pharma customers
  - QbD hasn't lived up to its hype
  - however, it can help design more robust manufacturing processes
  - albeit at a very high cost in terms of required resources
- Our assessment: QbD is very <u>effective</u>, but current methods leave a lot of room for <u>efficiency improvements</u>
  - efficiency can be improved through the "sound science" element of the QbD definition, appreciating we know more than the I/O structure

## Evolution in the use of experimental data to support design of robust products and processes



**Experiment** design method

Aim of experimental programme

Models used

Limitations / challenges of the approach




## Progress on turning the vision into reality

#### We are not starting from scratch




#### current focus of PSE Life Sciences



ADVANCED PROCESS MODELLING FORUM 2014

#### Several aspects are being addressed considered





Integrate with existing; devise new ones

Documentation & compliance

#### Several aspects are being addressed considered





#### Domain knowledge

- Manufacturing steps
- Biopharmaceutics
- Physical properties
- Material properties

## Model implementation (existing science)

- robustness
- compatibility
- documentation
- maintenance





- New oral absorption modelling tool
- Enhancements to gCRYSTAL & gSOLIDS
- Physical property package
- Filtration, wet milling
- In-vitro models
  - USP-2
  - ASD
- More enhancements to gCRYSTAL, gSOLIDS & gCOAS



#### Several aspects are being addressed considered




## Model development (new science)

- Academia, e.g.
   CMAC, C-SOPS,
   RCPE, SSPC, ...
- Pharma companies
- ..

#### Domain knowledge

- Manufacturing steps
- Biopharmaceutics
- Physical properties
- Material properties




- (Spray) drying modelling framework
  - different droplet / particle drying models
  - agglomeration
  - TSB project (Hossein Ahmadian's talk earlier today)
- Granulation modelling framework
  - HSWG, FBG, (screw granulation)
- Fed-fasted-fed dynamics
  - time varying pH and bile
     conc.

    ADVANCED PROCESS

#### Several aspects are being addressed considered






- Open platform for knowledge integration
- Parameter estimation (link to PAT), optimization (QbD)
  - Global Sensitivity Analysis
    - Different sources of variability/uncertainty
      - Covariance of estimated parameters
      - Common cause variability
      - Patient-to-patient variability
    - TSB funded activity to start May/June 2014
  - Multizonal CFD:EL-gPROMS interface
    - TSB spray drying project (Hossein Ahmadian's talk earlier today)
  - Multizonal DEM-gPROMS interface
    - C-SOPS (Dana Barrasso's talk later today)
    - TMAPPP



#### Several aspects are being addressed considered





- Different interests, priorities, skills and locations
- Appropriate interfaces
- Consistent knowledge
- Developer versions (Tier I users)



- Deployment of models via corporate intranet
- gE:Web Enterprise Web Publishing Solution

Publish and deploy gPROMS models via the web or intranet

The gPROMS Enterprise Web Publishing Solution makes the power of gPROMS models developed in the gPROMS ModelBuilder and the other members of the gPROMS product family accessible across the enterprise.



Standard versions (Tier II users)




Model-based control



#### Several aspects are being addressed considered





- Integration of modeling, experimentation, & computational chemistry
- From basic process development to scale up
- Integrate with existing; devise new ones
- Documentation & compliance

- gCRYSTAL-gSOLIDS-xxx interoperability
- Databases for
  - physical properties
    - complex phase structures
  - material properties
    - excipient and API lots; drug formulations
  - equipment characteristics
    - dimensions and operating constraints
  - physiology

hierarchy: personal > group > corporate > alliance > PSE

- Use of experimental data for PE
  - avoid copy-paste errors
  - data processing
    - aligning time stamps
    - filtering high frequency data






## Concluding remarks



#### Concluding remarks



SbP is a holistic approach to the development and optimization of drug manufacture and drug delivery systems



- supported by mechanistic APM tools and associated workflows
  - that are being enhanced on a continual basis
- being adopted by a rapidly increasing number of companies © 2014 Process Systems Enterprise Limited Slide 25

